三鑫醫療(300453.SZ):擬出資200萬元在國家級贛江新區設立全資子公司 進行慢性腎病管理研究與開發
格隆匯 9 月 24日丨三鑫醫療(300453.SZ)公佈,公司在血液淨化和終末期腎衰竭治療器械領域的研發、製造、渠道等優勢,進一步完善公司的產業佈局,延伸腎臟病管理產業鏈,服務更多的慢性腎臟病患者,公司擬使用自有資金貳佰萬元人民幣在中國(南昌)中醫藥科創城(位於國家級贛江新區)設立全資子公司江西漢方醫學科技有限公司(暫定名,最終以工商行政管理部門核准的信息為準,以下簡稱“漢方醫學”)。漢方醫學將開展通過中醫藥進行慢性腎病管理的研究與開發,打造慢性腎病管理平台。
公司於2020年9月24日召開了第四屆董事會第六次會議,審議並通過了《關於對外投資在國家級贛江新區設立全資子公司的議案》。根據《深圳證券交易所創業板股票上市規則》、《深圳證券交易所創業板上市公司規範運作指引》及《公司章程》的有關規定,公司本次對外投資屬於董事會決策權限範圍內事項,無需提交公司股東大會審議。本次對外投資不構成關聯交易,亦不構成中國證監會《上市公司重大資產重組管理辦法》規定的重大資產重組。
擬設立全資子公司的基本情況
1、公司名稱:江西漢方醫學科技有限公司(暫定名)
2、註冊地址:贛江新區(具體地點待定)
3、註冊資本:貳佰萬元人民幣
4、經營範圍:醫學研究和試驗發展;技術服務、技術開發、技術諮詢、技術交流、技術轉讓、技術推廣;信息諮詢服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.